Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.

Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, Cummings CT, Lee M, Glaros TG, Newton DL, Sather S, Zhang D, Kireev D, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.

J Med Chem. 2014 Aug 28;57(16):7031-41. doi: 10.1021/jm500749d. Epub 2014 Aug 6.

2.

Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies.

Hollingshead MG, Stockwin LH, Alcoser SY, Newton DL, Orsburn BC, Bonomi CA, Borgel SD, Divelbiss R, Dougherty KM, Hager EJ, Holbeck SL, Kaur G, Kimmel DJ, Kunkel MW, Millione A, Mullendore ME, Stotler H, Collins J.

BMC Genomics. 2014 May 22;15:393. doi: 10.1186/1471-2164-15-393.

3.

Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis.

Morrison BL, Mullendore ME, Stockwin LH, Borgel S, Hollingshead MG, Newton DL.

Cancer Med. 2013 Oct;2(5):687-700. doi: 10.1002/cam4.107. Epub 2013 Jul 23.

4.

Trypsin-mediated ¹⁸O/¹⁶O labeling for biomarker discovery.

Ye X, Chan KC, Prieto DA, Luke BT, Johann DJ Jr, Stockwin LH, Newton DL, Blonder J.

Methods Mol Biol. 2013;1002:133-49. doi: 10.1007/978-1-62703-360-2_12.

PMID:
23625401
5.

Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH.

PLoS One. 2012;7(8):e41401. doi: 10.1371/journal.pone.0041401. Epub 2012 Aug 3. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210.

6.

The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response.

Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL, Newton DL.

Cancer Chemother Pharmacol. 2012 Jul;70(1):207-12. doi: 10.1007/s00280-012-1868-0. Epub 2012 Apr 21. Erratum in: Cancer Chemother Pharmacol. 2012 Nov;70(5):763-4.

PMID:
22526412
7.

Challenges in plasma membrane phosphoproteomics.

Orsburn BC, Stockwin LH, Newton DL.

Expert Rev Proteomics. 2011 Aug;8(4):483-94. doi: 10.1586/epr.11.40. Review.

8.

A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.

Hancock CN, Stockwin LH, Han B, Divelbiss RD, Jun JH, Malhotra SV, Hollingshead MG, Newton DL.

Free Radic Biol Med. 2011 Jan 1;50(1):110-21. doi: 10.1016/j.freeradbiomed.2010.10.696. Epub 2010 Nov 4.

9.

Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.

Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG, Newton DL.

Int J Cancer. 2010 Dec 1;127(11):2510-9. doi: 10.1002/ijc.25499.

10.

Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.

Han B, Stockwin LH, Hancock C, Yu SX, Hollingshead MG, Newton DL.

J Proteome Res. 2010 Aug 6;9(8):4016-27. doi: 10.1021/pr100194d. Erratum in: J Proteome Res. 2011 Apr 1;10(4):2128.

11.

Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction.

Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, Slade D, Galal AM, Newton DL, Bumke MA.

Int J Cancer. 2009 Sep 15;125(6):1266-75. doi: 10.1002/ijc.24496. Erratum in: Int J Cancer. 2010 Dec;127(11):E1. Bumke, Maja A [added].

12.

Anti-CD22 Onconase: preparation and characterization.

Newton DL, Stockwin LH, Rybak SM.

Methods Mol Biol. 2009;525:425-43, xiv. doi: 10.1007/978-1-59745-554-1_22.

PMID:
19252847
13.

ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.

Stockwin LH, Yu SX, Stotler H, Hollingshead MG, Newton DL.

BMC Cancer. 2009 Feb 20;9:63. doi: 10.1186/1471-2407-9-63.

14.

Proteomic analysis identifies oxidative stress induction by adaphostin.

Stockwin LH, Bumke MA, Yu SX, Webb SP, Collins JR, Hollingshead MG, Newton DL.

Clin Cancer Res. 2007 Jun 15;13(12):3667-81.

15.

Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma.

Stockwin LH, Blonder J, Bumke MA, Lucas DA, Chan KC, Conrads TP, Issaq HJ, Veenstra TD, Newton DL, Rybak SM.

J Proteome Res. 2006 Nov;5(11):2996-3007.

PMID:
17081051
16.

Acquired amegakaryocytic thrombocytopenic purpura.

Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM.

Am J Hematol. 2006 Feb;81(2):132-5.

17.

Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.

Krauss J, Arndt MA, Vu BK, Newton DL, Seeber S, Rybak SM.

Biochem Biophys Res Commun. 2005 Jun 3;331(2):595-602.

PMID:
15850802
18.

A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells.

Arndt MA, Krauss J, Vu BK, Newton DL, Rybak SM.

J Immunother. 2005 May-Jun;28(3):245-51.

PMID:
15838381
19.

Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.

Krauss J, Arndt MA, Vu BK, Newton DL, Rybak SM.

Br J Haematol. 2005 Mar;128(5):602-9.

PMID:
15725080
20.

Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation.

Yang D, Chen Q, Rosenberg HF, Rybak SM, Newton DL, Wang ZY, Fu Q, Tchernev VT, Wang M, Schweitzer B, Kingsmore SF, Patel DD, Oppenheim JJ, Howard OM.

J Immunol. 2004 Nov 15;173(10):6134-42.

21.

Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme.

Krauss J, Arndt MA, Zhu Z, Newton DL, Vu BK, Choudhry V, Darbha R, Ji X, Courtenay-Luck NS, Deonarain MP, Richards J, Rybak SM.

Br J Cancer. 2004 May 4;90(9):1863-70.

22.

"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.

Rybak SM, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G, Sausville EA.

Cancer Res. 2003 Jun 1;63(11):2812-9.

23.

RNA cleavage and inhibition of protein synthesis by bleomycin.

Abraham AT, Lin JJ, Newton DL, Rybak S, Hecht SM.

Chem Biol. 2003 Jan;10(1):45-52.

PMID:
12573697
24.

Construction and characterization of RNase-based targeted therapeutics.

Newton DL, Futami J, Ruby D, Rybak SM.

Methods Mol Biol. 2003;207:283-304. No abstract available.

PMID:
12412481
25.

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics.

Hursey M, Newton DL, Hansen HJ, Ruby D, Goldenberg DM, Rybak SM.

Leuk Lymphoma. 2002 May;43(5):953-9. Review.

PMID:
12148905
26.
27.

Preparation of recombinant RNase single-chain antibody fusion proteins.

Newton DL, Rybak SM.

Mol Biotechnol. 2002 Jan;20(1):63-76. Review.

PMID:
11876300
28.

Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.

Newton DL, Ryback SM.

Expert Opin Biol Ther. 2001 Nov;1(6):995-1003. Review.

PMID:
11728231
29.

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.

Newton DL, Hansen HJ, Liu H, Ruby D, Iordanov MS, Magun BE, Goldenberg DM, Rybak SM.

Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):79-86. Review.

PMID:
11418304
30.

Preparation and preclinical characterization of RNase-based immunofusion proteins.

Newton DL, Rybak SM.

Methods Mol Biol. 2001;160:387-406. Review. No abstract available.

PMID:
11265299
31.

Differential requirement for the stress-activated protein kinase/c-Jun NH(2)-terminal kinase in RNAdamage-induced apoptosis in primary and in immortalized fibroblasts.

Iordanov MS, Wong J, Newton DL, Rybak SM, Bright RK, Flavell RA, Davis RJ, Magun BE.

Mol Cell Biol Res Commun. 2000 Aug;4(2):122-8.

PMID:
11170843
32.
33.

A gender-specific mRNA encoding a cytotoxic ribonuclease contains a 3' UTR of unusual length and structure.

Chen S, Le SY, Newton DL, Maizel JV Jr, Rybak SM.

Nucleic Acids Res. 2000 Jun 15;28(12):2375-82.

34.
35.

Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice.

Newton DL, Pollock D, DiTullio P, Echelard Y, Harvey M, Wilburn B, Williams J, Hoogenboom HR, Raus JC, Meade HM, Rybak SM.

J Immunol Methods. 1999 Dec 10;231(1-2):159-67.

PMID:
10648935
36.

RNA damage and inhibition of neoplastic endothelial cell growth: effects of human and amphibian ribonucleases.

Newton DL, Kaur G, Rhim JS, Sausville EA, Rybak SM.

Radiat Res. 2001 Jan;155(1 Pt 2):171-174.

PMID:
11121230
37.

Preparation of Recombinant RNase Single-Chain Antibody Fusion Proteins.

Newton DL, Rybak SM.

Methods Mol Med. 2000;25:77-95. doi: 10.1385/1-59259-075-6:77.

PMID:
21318842
38.

Construction of ribonuclease-antibody conjugates for selective cytotoxicity.

Newton DL, Rybak SM.

Methods Mol Med. 2000;25:27-35. doi: 10.1385/1-59259-075-6:27.

PMID:
21318838
39.

Natural and engineered cytotoxic ribonucleases: therapeutic potential.

Rybak SM, Newton DL.

Exp Cell Res. 1999 Dec 15;253(2):325-35. Review. No abstract available.

PMID:
10585255
40.

Uncloaking RNases.

Rybak SM, Newton DL.

Nat Biotechnol. 1999 May;17(5):408. No abstract available.

PMID:
10331782
41.

Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases.

Smith MR, Newton DL, Mikulski SM, Rybak SM.

Exp Cell Res. 1999 Feb 25;247(1):220-32.

PMID:
10047464
42.

Unique recombinant human ribonuclease and inhibition of Kaposi's sarcoma cell growth.

Newton DL, Rybak SM.

J Natl Cancer Inst. 1998 Dec 2;90(23):1787-91.

PMID:
9839518
43.
44.

Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector.

Cara A, Rybak SM, Newton DL, Crowley R, Rottschafer SE, Reitz MS Jr, Gusella GL.

Gene Ther. 1998 Jan;5(1):65-75.

45.

Cloning and cytotoxicity of a human pancreatic RNase immunofusion.

Zewe M, Rybak SM, Dübel S, Coy JF, Welschof M, Newton DL, Little M.

Immunotechnology. 1997 Jun;3(2):127-36.

PMID:
9237097
46.

Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapy.

Newton DL, Xue Y, Boqué L, Wlodawer A, Kung HF, Rybak SM.

Protein Eng. 1997 Apr;10(4):463-70.

PMID:
9194172
47.
48.

X-ray crystallographic structure of recombinant eosinophil-derived neurotoxin at 1.83 A resolution.

Mosimann SC, Newton DL, Youle RJ, James MN.

J Mol Biol. 1996 Jul 26;260(4):540-52.

PMID:
8759319
49.

Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.

Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL, Mikulski SM, Ardelt W, Riggs CW, Kung HF, Longo DL.

J Natl Cancer Inst. 1996 Jun 5;88(11):747-53.

PMID:
8637029
50.

Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.

Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM.

Biochemistry. 1996 Jan 16;35(2):545-53.

PMID:
8555226

Supplemental Content

Loading ...
Support Center